|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
260,040,000 |
Market
Cap: |
108.52(B) |
Last
Volume: |
905,443 |
Avg
Vol: |
1,634,038 |
52
Week Range: |
$304.75 - $446.08 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 543 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
77,148 |
177,399 |
290,659 |
653,862 |
Total Sell Value |
$32,455,469 |
$71,003,057 |
$110,033,743 |
$215,444,886 |
Total People Sold |
9 |
13 |
15 |
19 |
Total Sell Transactions |
29 |
46 |
71 |
150 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-26 |
4 |
AS |
$425.70 |
$1,278,803 |
D/D |
(3,004) |
55,325 |
|
-4% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-26 |
4 |
AS |
$425.70 |
$150,698 |
D/D |
(354) |
55,804 |
|
-4% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2024-02-26 |
4 |
AS |
$425.70 |
$1,804,542 |
D/D |
(4,239) |
25,813 |
|
-4% |
|
Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
|
2024-02-26 |
4 |
AS |
$425.70 |
$375,893 |
D/D |
(883) |
15,972 |
|
-4% |
|
Arbuckle Stuart A |
EVP, COO |
|
2024-02-26 |
4 |
AS |
$425.70 |
$2,142,974 |
D/D |
(5,034) |
49,691 |
|
-4% |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2024-02-26 |
4 |
AS |
$425.70 |
$375,893 |
D/D |
(883) |
7,965 |
|
-4% |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-23 |
4 |
D |
$431.79 |
$1,066,090 |
D/D |
(2,469) |
58,329 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-23 |
4 |
D |
$431.79 |
$1,428,793 |
D/D |
(3,309) |
56,158 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2024-02-23 |
4 |
D |
$431.79 |
$1,714,206 |
D/D |
(3,970) |
30,052 |
|
- |
|
Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
|
2024-02-23 |
4 |
D |
$431.79 |
$714,181 |
D/D |
(1,654) |
16,855 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2024-02-23 |
4 |
D |
$431.79 |
$1,428,793 |
D/D |
(3,309) |
36,939 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2024-02-23 |
4 |
D |
$431.79 |
$2,035,458 |
D/D |
(4,714) |
54,725 |
|
- |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2024-02-23 |
4 |
D |
$431.79 |
$357,522 |
D/D |
(828) |
8,848 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2024-02-23 |
4 |
D |
$431.79 |
$4,052,781 |
D/D |
(9,386) |
136,507 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2024-02-23 |
4 |
D |
$431.79 |
$1,428,793 |
D/D |
(3,309) |
53,583 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2024-02-21 |
4 |
AS |
$421.77 |
$1,519,637 |
D/D |
(3,603) |
59,439 |
|
-1% |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-21 |
4 |
AS |
$421.77 |
$1,345,868 |
D/D |
(3,191) |
60,798 |
|
-1% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-21 |
4 |
AS |
$421.77 |
$151,837 |
D/D |
(360) |
59,467 |
|
-1% |
|
Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
|
2024-02-21 |
4 |
AS |
$421.77 |
$506,546 |
D/D |
(1,201) |
18,509 |
|
-1% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2024-02-21 |
4 |
AS |
$421.77 |
$1,266,154 |
D/D |
(3,002) |
34,022 |
|
-1% |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-20 |
4 |
AS |
$420.79 |
$1,790,041 |
D/D |
(4,254) |
63,989 |
|
-1% |
|
Sachdev Amit |
EVP Chief Patient & Ext Af Off |
|
2024-02-20 |
4 |
D |
$420.58 |
$1,103,181 |
D/D |
(2,623) |
68,243 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2024-02-20 |
4 |
D |
$420.58 |
$2,952,051 |
D/D |
(7,019) |
145,893 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-20 |
4 |
AS |
$420.79 |
$201,979 |
D/D |
(480) |
59,827 |
|
-1% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2024-02-20 |
4 |
D |
$420.58 |
$1,418,616 |
D/D |
(3,373) |
60,307 |
|
- |
|
3256 Records found
|
|
Page 1 of 131 |
|
|